Cited by 32Tissue Engineering and Regenerative Medicine3D Printing in Biomedical ResearchDrug-Induced Hepatotoxicity and Protection

Long-term culture of human liver tissue with advanced hepatic functions

Open access
Ng, Soon Seng, Xiong, Anming, Nguyen, Khanh, Masek, Marilyn, No, Da Yoon, Elazar, Menashe, Shteyer, Eyal, Winters, Mark A. +6 more·2017·JCI Insight

Abstract

A major challenge for studying authentic liver cell function and cell replacement therapies is that primary human hepatocytes rapidly lose their advanced function in conventional, 2-dimensional culture platforms. Here, we describe the fabrication of 3-dimensional hexagonally arrayed lobular human liver tissues inspired by the liver’s natural architecture. The engineered liver tissues exhibit key features of advanced differentiation, such as human-specific cytochrome P450–mediated drug metabolism and the ability to support efficient infection with patient-derived inoculums of hepatitis C virus. The tissues permit the assessment of antiviral agents and maintain their advanced functions for over 5 months in culture. This extended functionality enabled the prediction of a fatal human-specific hepatotoxicity caused by fialuridine (FIAU), which had escaped detection by preclinical models and short-term clinical studies. The results obtained with the engineered human liver tissue in this study provide proof-of-concept determination of human-specific drug metabolism, demonstrate the ability to support infection with human hepatitis virus derived from an infected patient and subsequent antiviral drug testing against said infection, and facilitate detection of human-specific drug hepatotoxicity associated with late-onset liver failure. Looking forward, the scalability and biocompatibility of the scaffold are also ideal for future cell replacement therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.90853

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Basic human liver function was recapitulated by a PEG-based scaffold.

    “This result builds on previous work by the authors, in which basic human liver function was recapitulated by a PEG-based scaffold160.”

    From Towards organoid culture without Matrigel (2021) · cites this paper as [160]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Institute of Medicine Committee to Review the Fialuridine Clinical T. In: Manning FJ, Swartz M, eds. Review of the Fialuridine (FIAU) Clinical Trials. Washington (DC): National Academies Press (US); 1995.

Cited by

Sorted by citations

Authors
Ng, S. S., Xiong, A., Nguyen, K., Masek, M., No, D. Y., Elazar, M., Shteyer, E., Winters, M. A., Voedisch, A., Shaw, K., Rashid, S. T., Frank, C. W., Cho, N. J., & Glenn, J. S.
Affiliations
  • Nanyang Technological University (SG)
  • Stanford Medicine (US)
  • Shaare Zedek Medical Center (IL)
  • Department of Obstetrics and Gynecology,
  • Stanford University (US)
Corresponding author
Glenn, Jeffrey S.
Venue
JCI Insight
Published
2017-06-02
Volume
2
Issue
11
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2620572834
Cited by
32
References
42
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 5 · 2018: 6
FWCI
3.64
Type
journal article
Language
en
Open access
Locations
  • JCI Insight (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DR-NTU (Nanyang Technological University) (submittedVersion, cc-by-nc)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Burroughs Wellcome Fund (Clinical Scientist Award in Translational Research (J.S.G.))
  • National Research Foundation ((NRF-NRFF2011-01), the National Medical Research Council (NMRC/CBRG/0005/2012))
  • National Institutes of Health (U19AI109662 (J.S.G.), RO1AI099245 (J.S.G.))
Topics
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
hepatocyte differentiation, hepatitis C, antiviral drug testing, liver failure, cell replacement therapy, scaffold biocompatibility

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review